Fmr LLC raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 237.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 711,313 shares of the medical research company’s stock after buying an additional 500,513 shares during the quarter. Fmr LLC owned approximately 2.40% of Bio-Rad Laboratories worth $160,978,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of BIO. Canada Pension Plan Investment Board acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $113,000. Pacad Investment Ltd. acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $113,000. Turner Investments LLC acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $136,000. Capital Analysts LLC acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Bio-Rad Laboratories by 12.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 90 shares during the last quarter. Institutional investors own 62.84% of the company’s stock.

Bio-Rad Laboratories, Inc. (BIO) opened at 223.27 on Friday. The firm has a market cap of $6.62 billion, a price-to-earnings ratio of 441.25 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 1-year low of $154.89 and a 1-year high of $242.79. The company’s 50-day moving average price is $221.08 and its 200 day moving average price is $219.92.

Several equities analysts have recently commented on the company. Zacks Investment Research lowered Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 5th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $275.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, July 14th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $255.00 price target on shares of Bio-Rad Laboratories in a research note on Monday, September 18th. TheStreet lowered Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday, August 3rd. Finally, Wells Fargo & Company assumed coverage on Bio-Rad Laboratories in a research note on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $240.00.

In other news, EVP Michael Crowley sold 700 shares of Bio-Rad Laboratories stock in a transaction on Friday, August 11th. The stock was sold at an average price of $215.91, for a total value of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 28.29% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Fmr LLC Has $160.98 Million Holdings in Bio-Rad Laboratories, Inc. (BIO)” was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/fmr-llc-has-160-98-million-holdings-in-bio-rad-laboratories-inc-bio/1612303.html.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.